Company Results | Supalai (SPALI TB/HOLD/Bt15.90/Target: Bt16.10) SPALI reported 3Q25 earnings of Bt1.17b, down 41% yoy but up 6% qoq, outperforming our expectations primarily due to higher-than-anticipated other income. For 4Q25, presales should be supported by new project launches, while earnings are expected to remain broadly flat qoq but fall yoy due to a high base comparison. We remain cautious about its business outlook, given the backlog, aggressive promotional campaigns, and weak homebuy...
Top Stories Company Results | Betagro (BTG TB/BUY/Bt16.70/Target: Bt20.00) Betagro’s 3Q25 core profit was reported at Bt1,180m (up 14% yoy, but down 54% qoq). The key pressure on 3Q25 earnings qoq was a lower gross margin due to softer swine prices. We observe an upward trend in domestic swine prices in Nov 25 and expect the trend to continue into 1H26. Upgrade to BUY with a higher target price of Bt20.00. Company Results | CP Axtra (CPAXT TB/BUY/Bt20.00/Target: Bt24.00) 3Q25 earnings are we...
Greater China Sector Update | China And Hong Kong Property On 10 November, the State Council vowed to expand C-REITs for POEs. However, demand stays weak: home sales from 1-10 November in 28 mainland cities fell 45% yoy, with prices trending down. In Hong Kong, the potential supply of private homes rose 1% qoq, yet property prices and rents showed improving fundamentals. Maintain MARKET WEIGHT; favour mainland developers with strong retail portfolios (CR Land, Longfor); in Hong Kong, favour SHKP...
Greater China Sector Update | Macau Gaming Macau’s Oct 25 GGR was MOP$24.1b, increasing 32% mom and 16% yoy, and recovering to 91% of 2019’s level (vs a recovery of 83% in Sep 25). Oct 25’s GGR number beat market consensus by 4%, and set another post-COVID-19 record. For 10M25, GGR climbed to MOP$205.4b, up 8% yoy, and recovered to 83% of 2019’s level. Maintain OVERWEIGHT; Galaxy remains our top pick. Company Results | China Merchants Bank (3968 HK/HOLD/HK$48.64/Target: HK$51.00) CMB rep...
Company Update | Supalai (SPALI TB/HOLD/Bt17.10/Target: Bt16.10) Net profit is estimated at Bt948m for 3Q25 (-52% yoy, -14% qoq), pressured by fewer transfers and equity income, while gross margin is likely to improve qoq on a more favourable transfer mix. Presales momentum is expected to remain solid in 4Q25, mainly supported by the high-rise segment following new project launches. Although we remain optimistic about SPALI’s fundamentals, presales momentum, and 4Q25 earnings outlook, we stay c...
Top Stories Company Update | Central Plaza Hotel (CENTEL TB/BUY/Bt32.25/Target: Bt37.00) CENTEL is expected to report a 3Q25 net profit of Bt157m (-3.5% yoy), and core profit of Bt170m (+4.4% yoy) excluding one-offs, driven by a strong performance from hotels Mirage Pattaya and Centara Osaka. The food segment should see a slight margin expansion. CENTEL will benefit from the new tax deduction measure for hotel renovations, which will support the upgrades in Krabi and Hua Hin (to complete by 2Q...
Greater China Company Results | China Resources Building Materials Technology (1313 HK/BUY/HK$1.75 /Target: HK$2.06) CR Building Mat Tech’s 9M25 results were below expectations, with earnings up 7.3% yoy to Rmb331m on lower coal costs. Weather disruptions weighed on 3Q25 cement sales volume, while Guangdong prices stayed soft. Aggregates turned loss-making, prompting capex cuts. Management guided 2025 sales of 55m tonnes (-10.9% yoy) and highlighted a planned capacity-exit fund as a medium-term ...
A director at Supalai Public Company Limited bought 1,200,000 shares at 15.710THB and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the la...
SPALI reported a net profit of Bt1.1b for 2Q25, down 31% yoy but up 173% qoq. The results fell short of our and consensus estimates. Although SPALI’s earnings are expected to be stronger in 2H25, we remain cautious about the economic conditions and intensifying competition. The company has announced an interim dividend with a yield of about 3.5%. Maintain HOLD. Target price: Bt14.70.
KEY HIGHLIGHTS Results Amata Corporation (AMATA TB/BUY/Bt16.50/Target: Bt25.00) 2Q25: Earnings below expectations. AP Thailand (AP TB/BUY/Bt7.65/Target: Bt9.60) 2Q25: Earnings in line, optimistic 3Q25 outlook. Bangkok Commercial Asset Management (BAM TB/BUY/Bt8.40/Target: Bt10.00) 2Q25: Results in line with consensus; highest bottom line in the past 22 quarters. Bangkok Dusit Medical Services (BDMS TB/BUY...
We expect SPALI to post a strong qoq earnings recovery in 2Q25, although earnings are likely to be lower on a yoy basis. The qoq improvement is expected to be driven by improving transfer activity and equity income. However, we remain cautious on the outlook for 2H25, given the challenging economic conditions and intensifying competition. SPALI has scaled down its launch pipeline plans for 2025 and is unlikely to achieve its full-year presales targets. Maintain HOLD. Target price: Bt14.70.
GREATER CHINA Sector Automobile: Weekly: PV sales growth turned negative yoy, despite a 7% wow rebound. Maintain MARKET WEIGHT on the sector. Top BUYs: CATL, Geely and Tuopu. Property Management: 1H25 results preview: SOEs' performance is broadly in line with expectations, change our top pick to CR Mixc from COPH. Update Aier Eye Hospital Group (300015 CH/BUY/Rmb13.36/Target: Rmb16.70): Weak economic conditions cloud optometry and refractory businesses in 2Q25. INDONESIA Update Telkom Indonesia...
GREATER CHINA Economics Economic Activity Mixed bag for May. Sector Property Property market weakens further in May 25, with diverging city-tier performance. INDONESIA Initiate Coverage Bumi Resources Minerals (BRMS IJ/BUY/Rp454/Target: Rp610) Soaring to new heights; initiate coverage with BUY. MALAYSIA Update Press Metal ...
SPALI reported a net profit of Bt405m for 1Q25, down 34% yoy and 80% qoq. The results fell short of our and consensus estimates. The earnings were pressured by weakened transfers. The company has announced a share repurchase programme that will take place over six months. 2Q25 earnings are expected to decline yoy but improve qoq due to a backlog. Maintain HOLD. Target price: Bt14.70.
KEY HIGHLIGHTS Results Bangchak Corporation (BCP TB/BUY/Bt38.00/Target: Bt45.00) 1Q25: Soft results, but better than expected; likely to see a strong rebound in 2Q25. COM7 (COM7 TB/BUY/Bt21.20/Target: Bt29.50) 1Q25: Better-than-expected earnings. CP ALL (CPALL TB/BUY/Bt51.50/Target: Bt79.00) 1Q25: Stronger-than-expected earnings. GFPT Plc. (GFPT TB/BUY/Bt9.80/Target: Bt13.40) ...
We expect SPALI to post weak results in 1Q25, with net profit projected at Bt475m (–23% yoy, –76% qoq), primarily pressured by slower transfer momentum due to a shrinking backlog and subdued demand. Although we expect earnings to improve qoq in 2Q25, presales momentum is expected to continue facing multiple headwinds. Achieving the full-year targets in 2025 for both presales and transfers remains challenging. Maintain HOLD. Target price: Bt18.20.
KEY HIGHLIGHTS Results Delta Electronics (DELTA TB/SELL/Bt82.00/Target: Bt50.00) 1Q25: Earnings beat on better gross margin and lower SG&A-to-sales. Update Plan B Media (PLANB TB/BUY/Bt5.20/Target: Bt7.70) Neutral view on 1Q25 results; positive view on upcoming deals. Supalai (SPALI TB/HOLD/Bt16.40/Target: Bt18.20) Weak results expected in 1Q25.
GREATER CHINA Sector Automobile: Weekly: Takeaways from Shanghai Auto Show 2025. 1Q25 results review for BYD, GWM and GAC. Maintain MARKET WEIGHT. Top BUYs: BYD, Geely and Desay SV. Consumer: Politburo meeting: Emphasising income improvement and service consumption; prefer consumer companies with strong cost control and domestic focus. Results BYD Company (1211 HK/BUY/HK$397.00/Target: HK$510.00): 1Q25: Earnings double yoy, in line. Maintain BUY. Target price: HK$510.00. EVE Energy (300014 HK/BU...
GREATER CHINA Results COSCO SHIPPING Ports (1199 HK/BUY/HK$4.78/Target: HK$5.90) 2024: Core earnings in line; expect low single digit throughput growth in 2025. CSPC Innovation Pharmaceutical Co (300765 CH/BUY/Rmb37.00/Target: Rmb50.00) 2024: Smooth progress in R&D promises bright long-term outlook. Hansoh Pharmaceutical Group Company (3692 HK/BUY/HK$20.10/Target:HK$29.00) 2024: Results beat; strong growth momentum continues. Meituan (3690 HK/BUY/HK$167.60/Target: HK$216.00) ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.